Swiss Life Sciences Stock News

Dividend approval and board refresh put Galderma in focus Galderma Group (SWX:GALD) drew fresh attention after its Annual General Meeting approved a CHF 0.35 per share dividend from capital contribution reserves and confirmed new Board members, including an independent director and two L’Oréal representatives. See our latest analysis for Galderma Group. At a CHF163.8 share price, Galderma’s recent AGM outcomes appear to have supported sentiment, with 1-month and 3-month share price returns of...

ABB (SWX:ABBN) has launched HiPerGuard 34.5kV, a new medium voltage UPS solution targeted at AI focused data centers. The system supports direct grid connection and is designed to deliver significant efficiency gains for large scale data infrastructure. HiPerGuard 34.5kV has received UL 9540 certification, covering integrated battery energy storage systems. The product is being positioned for deployment across key global regions to support rising power and flexibility needs in AI and data...

Q1 trading update puts SGS (SWX:SGSN) in focus SGS (SWX:SGSN) has come onto investors’ radar after its Q1 2026 sales and trading statement call on 23 April, prompting fresh attention on how the testing, inspection and certification group is currently positioned. See our latest analysis for SGS. Following the Q1 2026 trading update, SGS’s share price at CHF84.64 reflects mixed momentum, with a 1 day share price return of 0.76% but a 90 day share price return showing an 8.79% decline, while the...

In late April 2026, SIG announced a two-phase expansion of its Querétaro plant that will double capacity to 3 billion packs annually by 2028, integrate processes like extrusion, and support nearshoring by shifting some production from Europe to Mexico. This move positions Querétaro as SIG’s main North American manufacturing hub, improving regional responsiveness for food and beverage customers while modestly increasing local employment and operational scale in Mexico. We’ll now consider how...

Wondering if Sandoz Group shares still offer value after a strong run, or if most of the opportunity is already priced in? This breakdown will help you assess how the current price compares with fundamentals. The stock last closed at CHF 62.54, with a 7 day return of a 3.1% decline, a 30 day return of 1.3%, and a 1 year return of 76.9% that has attracted significant investor attention. Recent news has focused on Sandoz Group as an established generics and biosimilars business following its...

Wondering if Logitech International at around US$76.74 is priced for opportunity or already reflects the story? This article walks you through what the numbers are actually saying about the stock today. The share price shows mixed recent returns, with 2.0% over the past week and 6.1% over the last month, set against a 3.4% decline year to date but a 25.5% gain over one year and 42.9% over three years, while the five year return stands at a 17.3% decline. Recent headlines around Logitech have...

If you are wondering whether Roche Holding is priced attractively or trading rich right now, the starting point is to look past the ticker and focus on what the current share price implies about value. Roche Holding shares recently closed at CHF318.40, with returns of 2.0% decline over 7 days, 1.2% over 30 days, 2.2% decline year to date, 21.9% over 1 year, 25.2% over 3 years, and 25.5% over 5 years. This gives you a mix of short term softness and longer term gains to interpret. Recent news...

As the pan-European STOXX Europe 600 Index experiences a decline, with defensive sectors like utilities and telecoms showing relative strength amid geopolitical tensions, investors are increasingly on the lookout for overlooked opportunities in the market. In this environment, identifying stocks with strong fundamentals and resilience to economic fluctuations can be crucial for navigating uncertainty.

As European markets navigate a landscape marked by geopolitical tensions and economic uncertainties, major indices such as the STOXX Europe 600 have recently experienced downturns, reflecting broader concerns over energy prices and consumer confidence. In this environment, growth companies with high insider ownership can offer unique insights into potential resilience and alignment of interests between management and shareholders.

Why ABB (SWX:ABBN) Is Back on Investors’ Radar ABB (SWX:ABBN) has attracted fresh attention after a strong run in recent months, prompting investors to reassess how its electrification, motion, and automation businesses align with wider industrial and infrastructure trends. See our latest analysis for ABB. With the share price at CHF78.44, ABB has seen strong recent momentum, including a 24.0% 1 month share price return and an 84.3% 1 year total shareholder return, which puts recent gains...

Nestlé is rolling out an industry first integration between CreativeX and CreatorIQ in its creator led advertising. The company is using AI powered quality controls to bring consistent creative standards to creator campaigns across global markets. This move extends the same level of scrutiny used in traditional media to Nestlé's creator partnerships. For investors tracking SWX:NESN, this shift in creator marketing comes as the shares trade at around CHF79.05 and have seen a 3.4% gain year...

Why the latest trial results matter for Roche Holding (SWX:ROG) Roche Holding (SWX:ROG) has put fresh clinical data in front of investors, with fenebrutinib hitting primary and secondary endpoints in two Phase III trials in relapsing multiple sclerosis. This comes alongside FDA acceptance of a supplemental filing for Gazyva/Gazyvaro in systemic lupus erythematosus. The FENhance 1 and 2 studies reported that fenebrutinib cut annualised relapse rates by 51.1% and 58.5% versus teriflunomide over...

Amrize (SWX:AMRZ) opened Q1 2026 with revenue of US$2.2b and a basic EPS loss of US$0.21, off a net income loss of US$116m for the quarter. Over the last year, the company has seen quarterly revenue move between US$2.1b and US$3.7b, while basic EPS has ranged from a loss of US$0.15 to a high of US$0.99. This gives investors a clear view of how earnings power can swing with the cycle. With trailing 12 month EPS at US$2.09 on net income of US$1.2b and margins easing from 10.6% to 9.7%, the...

Recent share performance and business scale Novartis (SWX:NOVN) has drawn investor attention after a period where the share price shows a 1 day return of 1.2%, a past week return of a 1.9% decline, and a month return of a 5.4% decline. Over the past 3 months, the stock shows a 0.8% decline, while the year to date return stands at 4.5%. The 1 year total return is 24.5%, with 3 year and 5 year total returns of 43.1% and 82.4% respectively. The company reports revenue of $56.6b and net income of...

VAT Group (SWX:VACN) reported first quarter 2026 sales of CHF 221 million and issued new guidance for the second quarter, while reiterating its full year 2026 outlook. See our latest analysis for VAT Group. VAT Group’s latest guidance and first quarter update come after a strong run in the share price, with a 30 day share price return of 23.02% and a 1 year total shareholder return of 103.54%. This suggests momentum has picked up recently even as investors continue to reassess long term...

Readers hoping to buy St. Galler Kantonalbank AG ( VTX:SGKN ) for its dividend will need to make their move shortly, as...

Santhera Pharmaceuticals Holding (SWX:SANN) has opened FY 2025 with first half revenue of CHF 24.0 million and a basic EPS loss of CHF 3.04, with trailing 12 month figures showing revenue of CHF 49.0 million and a basic EPS loss of CHF 5.41, so profitability remains out of reach for now. The company has seen total revenue across the last three reported half year periods move from CHF 14.1 million in H1 2024 to CHF 25.0 million in H2 2024 and CHF 24.0 million in H1 2025, while basic EPS...

Why Sandoz Group is on investors’ radar today Sandoz Group (SWX:SDZ) has drawn fresh attention after its recent share performance and updated fundamentals, prompting investors to reassess how its generic and biosimilar portfolio compares with the current valuation. See our latest analysis for Sandoz Group. At a share price of CHF61.26, Sandoz Group has seen short term softness, with a 1 day share price return of 2.23% decline and a 7 day share price return of 2.82% decline, while its 1 year...

UBS Group Q1 2026 Earnings Snapshot UBS Group (SWX:UBSG) has opened Q1 2026 reporting season following a solid 2025 finish, with Q4 revenue at US$12.8 billion and basic EPS of US$0.39 anchoring the latest set of numbers. The bank reported quarterly revenue rising from US$11.4 billion in Q4 2024 to US$12.8 billion in Q4 2025, while trailing twelve month EPS reached US$2.46 alongside net income of US$7.8 billion. This provides a clear view of how earnings have moved in line with the top line...

What the G512 X launch might mean for Logitech International (SWX:LOGN) Logitech International (SWX:LOGN) just put its gaming peripheral business in focus with the launch of the Logitech G512 X TMR Analog/Mechanical Gaming Keyboard, a modular device built around customization and analog precision. See our latest analysis for Logitech International. At a share price of CHF76.28, Logitech International has delivered an 11.39% 90 day share price return and a 20.09% 1 year total shareholder...

Amrize (SWX:AMRZ) is extending its "Made in America" cement label to four additional US plants as part of a wider push into domestic manufacturing. The company is increasing investment in its US production footprint, aiming to support local jobs and reinforce supply certainty for American customers. At its recent AGM, Amrize also approved changes to its Board of Directors, updating its governance structure. With a current share price of CHF44.94, Amrize sits in the mid cap range of the...

As European markets face heightened geopolitical risks and economic uncertainties, the pan-European STOXX Europe 600 Index recently experienced a decline, with defensive sectors like utilities and telecoms showing resilience. In this environment, identifying stocks with strong fundamentals and growth potential becomes crucial for investors seeking opportunities amid volatility.

Novartis (SWX:NOVN) opened 2026 with Q1 revenue of US$13.5b and basic EPS of US$1.65, set against trailing twelve month figures of US$56.6b in revenue and EPS of US$7.03 that frame the latest quarter in a broader earnings context. Over recent periods, quarterly revenue has ranged from US$13.5b to US$14.8b, while basic EPS has moved between US$1.26 and US$2.07. This gives investors a clear read on how current earnings sit within the recent run rate and what that implies for margins heading...

Lonza Group (SWX:LONN) has moved into focus after joining a funded research collaboration with Simulations Plus and the U.S. Food and Drug Administration to build predictive frameworks for amorphous solid dispersion drug products. See our latest analysis for Lonza Group. Despite the new FDA-backed collaboration and recent conference appearances, Lonza Group’s 1-day share price return of 1.83% comes against a weaker backdrop. The 90-day share price return of 12.5% and the 1-year total...